Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 24, 2022 16:04 ET | Source: Vir Biotechnology, Inc.

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results

– Significant progress made increasing global patient access to sotrovimab; approximately 1.7 million doses sold to date – – $917.2 million of sotrovimab collaboration revenue recognized in 2021 – –...
February 10, 2022 16:02 ET | Source: Vir Biotechnology, Inc.

Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2021 Financial Results on February 24, 2022

SAN FRANCISCO, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the fourth quarter...
January 13, 2022 09:02 ET | Source: Vir Biotechnology, Inc.

GSK and Vir Submit Emergency Use Authorization Application to FDA for Intramuscular Administration of Sotrovimab for the Early Treatment of COVID-19

– If authorized, would provide the option for intramuscular administration of sotrovimab, in addition to currently authorized intravenous administration – – Submission follows COMET-TAIL Phase 3...
January 11, 2022 07:12 ET | Source: Vir Biotechnology, Inc.

GSK and Vir Biotechnology Announce United States Government Agreement to Purchase Additional Supply of Sotrovimab, Authorized for the Early Treatment of COVID-19

– 600,000 additional doses to be supplied to the US government for distribution in Q1 2022, enabling further access to sotrovimab nationwide – – Brings total number of doses secured to date through...
December 14, 2021 16:40 ET | Source: Vir Biotechnology, Inc.

Preclinical Data Highlight the Significant Antigenic Shift of the Omicron SARS-CoV-2 Variant and its Effect on the Neutralizing Activity of Monoclonal Antibodies, Convalescent Antibodies and Vaccine-Elicited Antibodies

– Data demonstrate sotrovimab, developed by Vir in conjunction with GlaxoSmithKline, continues to retain in vitro neutralizing activity against all tested variants of concern, including Omicron – SAN...
August 23, 2021 08:30 ET | Source: Vir Biotechnology, Inc.

Vir Biotechnology Announces First Marketing Authorization for its First Commercial Product, Sotrovimab, Granted in Australia

SAN FRANCISCO, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the first marketing authorization, granted in Australia, for its first commercial product,...
January 26, 2021 08:00 ET | Source: Vir Biotechnology, Inc.

Initial Data from Ongoing Phase 1 Trial of VIR-3434 for Chronic Hepatitis B Virus Infection Demonstrates Significant and Rapid Reduction in Hepatitis B Surface Antigen

– Novel HBV-neutralizing monoclonal antibody with therapeutic vaccine potential demonstrated a mean HBsAg reduction from baseline of 1.3 log10 IU/mL by day eight – SAN FRANCISCO, Jan. 26, 2021 ...
October 06, 2020 08:18 ET | Source: Vir Biotechnology, Inc.

Vir Biotechnology and GSK announce global expansion to Phase 3 of COMET-ICE study evaluating VIR-7831 for the treatment of COVID-19

Independent Data Monitoring Committee recommended on September 30, 2020 that the study continue into Phase 3 based on a positive evaluation of safety and tolerability data from the Phase 2...
September 24, 2020 08:00 ET | Source: Vir Biotechnology, Inc.

Vir Biotechnology Publishes New Research Characterizing Antibody Response to SARS-CoV-2 in the Journal Cell

– Largest-to-date analysis of serum samples from nearly 650 SARS-CoV-2-infected patients – – High-resolution serology advances understanding of variations in natural antibody response to SARS-CoV-2...